nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabilone—Dronabinol—CYP1A1—liver cancer	0.0514	1	CrCbGaD
Nabilone—Aphthous stomatitis—Sorafenib—liver cancer	0.0371	0.04	CcSEcCtD
Nabilone—Drug interaction—Sorafenib—liver cancer	0.0188	0.0202	CcSEcCtD
Nabilone—Aphthous stomatitis—Epirubicin—liver cancer	0.0137	0.0148	CcSEcCtD
Nabilone—Muscle relaxant therapy—Epirubicin—liver cancer	0.0129	0.0139	CcSEcCtD
Nabilone—Aphthous stomatitis—Doxorubicin—liver cancer	0.0127	0.0137	CcSEcCtD
Nabilone—Hypotonia—Epirubicin—liver cancer	0.0122	0.0132	CcSEcCtD
Nabilone—Mood swings—Sorafenib—liver cancer	0.012	0.0129	CcSEcCtD
Nabilone—Muscle relaxant therapy—Doxorubicin—liver cancer	0.012	0.0129	CcSEcCtD
Nabilone—Hypothermia—Epirubicin—liver cancer	0.0115	0.0124	CcSEcCtD
Nabilone—Body temperature decreased—Epirubicin—liver cancer	0.0115	0.0124	CcSEcCtD
Nabilone—Hypotonia—Doxorubicin—liver cancer	0.0113	0.0122	CcSEcCtD
Nabilone—Gastritis—Sorafenib—liver cancer	0.0112	0.012	CcSEcCtD
Nabilone—Body temperature decreased—Doxorubicin—liver cancer	0.0106	0.0114	CcSEcCtD
Nabilone—Hypothermia—Doxorubicin—liver cancer	0.0106	0.0114	CcSEcCtD
Nabilone—Stomatitis—Sorafenib—liver cancer	0.0095	0.0102	CcSEcCtD
Nabilone—Epistaxis—Sorafenib—liver cancer	0.00919	0.00989	CcSEcCtD
Nabilone—Scotoma—Epirubicin—liver cancer	0.00848	0.00912	CcSEcCtD
Nabilone—Amblyopia—Epirubicin—liver cancer	0.00834	0.00897	CcSEcCtD
Nabilone—Tinnitus—Sorafenib—liver cancer	0.00815	0.00877	CcSEcCtD
Nabilone—Flushing—Sorafenib—liver cancer	0.00812	0.00873	CcSEcCtD
Nabilone—Scotoma—Doxorubicin—liver cancer	0.00784	0.00844	CcSEcCtD
Nabilone—Arrhythmia—Sorafenib—liver cancer	0.00781	0.00841	CcSEcCtD
Nabilone—Amblyopia—Doxorubicin—liver cancer	0.00771	0.0083	CcSEcCtD
Nabilone—Anaemia—Sorafenib—liver cancer	0.00704	0.00757	CcSEcCtD
Nabilone—Thinking abnormal—Epirubicin—liver cancer	0.00703	0.00756	CcSEcCtD
Nabilone—Syncope—Sorafenib—liver cancer	0.00683	0.00735	CcSEcCtD
Nabilone—Leukopenia—Sorafenib—liver cancer	0.00681	0.00733	CcSEcCtD
Nabilone—Loss of consciousness—Sorafenib—liver cancer	0.00669	0.0072	CcSEcCtD
Nabilone—Cough—Sorafenib—liver cancer	0.00664	0.00715	CcSEcCtD
Nabilone—Hypertension—Sorafenib—liver cancer	0.00657	0.00707	CcSEcCtD
Nabilone—Coordination abnormal—Epirubicin—liver cancer	0.00655	0.00705	CcSEcCtD
Nabilone—Neck pain—Epirubicin—liver cancer	0.00651	0.00701	CcSEcCtD
Nabilone—Thinking abnormal—Doxorubicin—liver cancer	0.00651	0.007	CcSEcCtD
Nabilone—Myalgia—Sorafenib—liver cancer	0.00648	0.00697	CcSEcCtD
Nabilone—Arthralgia—Sorafenib—liver cancer	0.00648	0.00697	CcSEcCtD
Nabilone—Abnormal dreams—Epirubicin—liver cancer	0.00636	0.00684	CcSEcCtD
Nabilone—Dry mouth—Sorafenib—liver cancer	0.00634	0.00682	CcSEcCtD
Nabilone—Infection—Sorafenib—liver cancer	0.00617	0.00664	CcSEcCtD
Nabilone—Shock—Sorafenib—liver cancer	0.00611	0.00658	CcSEcCtD
Nabilone—Coordination abnormal—Doxorubicin—liver cancer	0.00606	0.00653	CcSEcCtD
Nabilone—Neck pain—Doxorubicin—liver cancer	0.00603	0.00649	CcSEcCtD
Nabilone—Dry eye—Epirubicin—liver cancer	0.00594	0.0064	CcSEcCtD
Nabilone—Anorexia—Sorafenib—liver cancer	0.00592	0.00637	CcSEcCtD
Nabilone—Abnormal dreams—Doxorubicin—liver cancer	0.00589	0.00633	CcSEcCtD
Nabilone—Coma—Epirubicin—liver cancer	0.00588	0.00633	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00566	0.00609	CcSEcCtD
Nabilone—Mental disability—Epirubicin—liver cancer	0.00559	0.00601	CcSEcCtD
Nabilone—Dyspnoea—Sorafenib—liver cancer	0.00554	0.00596	CcSEcCtD
Nabilone—Dry eye—Doxorubicin—liver cancer	0.0055	0.00592	CcSEcCtD
Nabilone—Dyspepsia—Sorafenib—liver cancer	0.00547	0.00588	CcSEcCtD
Nabilone—Coma—Doxorubicin—liver cancer	0.00544	0.00586	CcSEcCtD
Nabilone—Decreased appetite—Sorafenib—liver cancer	0.0054	0.00581	CcSEcCtD
Nabilone—Fatigue—Sorafenib—liver cancer	0.00536	0.00576	CcSEcCtD
Nabilone—Photosensitivity—Epirubicin—liver cancer	0.00532	0.00573	CcSEcCtD
Nabilone—Constipation—Sorafenib—liver cancer	0.00531	0.00572	CcSEcCtD
Nabilone—Pain—Sorafenib—liver cancer	0.00531	0.00572	CcSEcCtD
Nabilone—Mental disability—Doxorubicin—liver cancer	0.00517	0.00556	CcSEcCtD
Nabilone—Gastrointestinal pain—Sorafenib—liver cancer	0.00508	0.00547	CcSEcCtD
Nabilone—Hot flush—Epirubicin—liver cancer	0.00499	0.00537	CcSEcCtD
Nabilone—Increased appetite—Epirubicin—liver cancer	0.00497	0.00535	CcSEcCtD
Nabilone—Menopausal symptoms—Epirubicin—liver cancer	0.00495	0.00533	CcSEcCtD
Nabilone—Photosensitivity—Doxorubicin—liver cancer	0.00492	0.0053	CcSEcCtD
Nabilone—Abdominal pain—Sorafenib—liver cancer	0.00491	0.00529	CcSEcCtD
Nabilone—Body temperature increased—Sorafenib—liver cancer	0.00491	0.00529	CcSEcCtD
Nabilone—Cerebrovascular accident—Epirubicin—liver cancer	0.00477	0.00513	CcSEcCtD
Nabilone—Hot flush—Doxorubicin—liver cancer	0.00462	0.00497	CcSEcCtD
Nabilone—Increased appetite—Doxorubicin—liver cancer	0.0046	0.00495	CcSEcCtD
Nabilone—Affect lability—Epirubicin—liver cancer	0.0046	0.00495	CcSEcCtD
Nabilone—Menopausal symptoms—Doxorubicin—liver cancer	0.00458	0.00493	CcSEcCtD
Nabilone—Hypersensitivity—Sorafenib—liver cancer	0.00458	0.00493	CcSEcCtD
Nabilone—Face oedema—Epirubicin—liver cancer	0.00451	0.00485	CcSEcCtD
Nabilone—Asthenia—Sorafenib—liver cancer	0.00446	0.0048	CcSEcCtD
Nabilone—Mood swings—Epirubicin—liver cancer	0.00443	0.00476	CcSEcCtD
Nabilone—Cerebrovascular accident—Doxorubicin—liver cancer	0.00441	0.00475	CcSEcCtD
Nabilone—Pruritus—Sorafenib—liver cancer	0.0044	0.00473	CcSEcCtD
Nabilone—Ataxia—Epirubicin—liver cancer	0.00439	0.00473	CcSEcCtD
Nabilone—Orthostatic hypotension—Epirubicin—liver cancer	0.00427	0.00459	CcSEcCtD
Nabilone—Affect lability—Doxorubicin—liver cancer	0.00425	0.00458	CcSEcCtD
Nabilone—Diarrhoea—Sorafenib—liver cancer	0.00425	0.00457	CcSEcCtD
Nabilone—Face oedema—Doxorubicin—liver cancer	0.00417	0.00449	CcSEcCtD
Nabilone—Gastritis—Epirubicin—liver cancer	0.00413	0.00445	CcSEcCtD
Nabilone—Dizziness—Sorafenib—liver cancer	0.00411	0.00442	CcSEcCtD
Nabilone—Mood swings—Doxorubicin—liver cancer	0.0041	0.00441	CcSEcCtD
Nabilone—Ataxia—Doxorubicin—liver cancer	0.00406	0.00437	CcSEcCtD
Nabilone—Vomiting—Sorafenib—liver cancer	0.00395	0.00425	CcSEcCtD
Nabilone—Orthostatic hypotension—Doxorubicin—liver cancer	0.00395	0.00425	CcSEcCtD
Nabilone—Rash—Sorafenib—liver cancer	0.00392	0.00422	CcSEcCtD
Nabilone—Dermatitis—Sorafenib—liver cancer	0.00391	0.00421	CcSEcCtD
Nabilone—Headache—Sorafenib—liver cancer	0.00389	0.00419	CcSEcCtD
Nabilone—Gastritis—Doxorubicin—liver cancer	0.00383	0.00412	CcSEcCtD
Nabilone—Pollakiuria—Epirubicin—liver cancer	0.00373	0.00401	CcSEcCtD
Nabilone—Nausea—Sorafenib—liver cancer	0.00369	0.00397	CcSEcCtD
Nabilone—Photosensitivity reaction—Epirubicin—liver cancer	0.00369	0.00397	CcSEcCtD
Nabilone—Drowsiness—Epirubicin—liver cancer	0.0036	0.00387	CcSEcCtD
Nabilone—Stomatitis—Epirubicin—liver cancer	0.00351	0.00378	CcSEcCtD
Nabilone—Pollakiuria—Doxorubicin—liver cancer	0.00345	0.00371	CcSEcCtD
Nabilone—Photosensitivity reaction—Doxorubicin—liver cancer	0.00341	0.00367	CcSEcCtD
Nabilone—Epistaxis—Epirubicin—liver cancer	0.0034	0.00365	CcSEcCtD
Nabilone—Drowsiness—Doxorubicin—liver cancer	0.00333	0.00358	CcSEcCtD
Nabilone—Stomatitis—Doxorubicin—liver cancer	0.00325	0.00349	CcSEcCtD
Nabilone—Hypoaesthesia—Epirubicin—liver cancer	0.00322	0.00346	CcSEcCtD
Nabilone—Pharyngitis—Epirubicin—liver cancer	0.00321	0.00345	CcSEcCtD
Nabilone—Epistaxis—Doxorubicin—liver cancer	0.00314	0.00338	CcSEcCtD
Nabilone—Visual impairment—Epirubicin—liver cancer	0.00311	0.00335	CcSEcCtD
Nabilone—Eye disorder—Epirubicin—liver cancer	0.00302	0.00325	CcSEcCtD
Nabilone—Tinnitus—Epirubicin—liver cancer	0.00301	0.00324	CcSEcCtD
Nabilone—Flushing—Epirubicin—liver cancer	0.003	0.00323	CcSEcCtD
Nabilone—Hypoaesthesia—Doxorubicin—liver cancer	0.00298	0.0032	CcSEcCtD
Nabilone—Pharyngitis—Doxorubicin—liver cancer	0.00297	0.00319	CcSEcCtD
Nabilone—Chills—Epirubicin—liver cancer	0.0029	0.00312	CcSEcCtD
Nabilone—Arrhythmia—Epirubicin—liver cancer	0.00289	0.00311	CcSEcCtD
Nabilone—Visual impairment—Doxorubicin—liver cancer	0.00288	0.0031	CcSEcCtD
Nabilone—Eye disorder—Doxorubicin—liver cancer	0.00279	0.00301	CcSEcCtD
Nabilone—Tinnitus—Doxorubicin—liver cancer	0.00279	0.003	CcSEcCtD
Nabilone—Flushing—Doxorubicin—liver cancer	0.00278	0.00299	CcSEcCtD
Nabilone—Tension—Epirubicin—liver cancer	0.00276	0.00297	CcSEcCtD
Nabilone—Nervousness—Epirubicin—liver cancer	0.00273	0.00294	CcSEcCtD
Nabilone—Back pain—Epirubicin—liver cancer	0.00272	0.00293	CcSEcCtD
Nabilone—Chills—Doxorubicin—liver cancer	0.00268	0.00289	CcSEcCtD
Nabilone—Arrhythmia—Doxorubicin—liver cancer	0.00267	0.00287	CcSEcCtD
Nabilone—Vision blurred—Epirubicin—liver cancer	0.00265	0.00285	CcSEcCtD
Nabilone—Ill-defined disorder—Epirubicin—liver cancer	0.00261	0.00281	CcSEcCtD
Nabilone—Anaemia—Epirubicin—liver cancer	0.0026	0.0028	CcSEcCtD
Nabilone—Agitation—Epirubicin—liver cancer	0.00259	0.00278	CcSEcCtD
Nabilone—Tension—Doxorubicin—liver cancer	0.00255	0.00275	CcSEcCtD
Nabilone—Malaise—Epirubicin—liver cancer	0.00254	0.00273	CcSEcCtD
Nabilone—Nervousness—Doxorubicin—liver cancer	0.00253	0.00272	CcSEcCtD
Nabilone—Vertigo—Epirubicin—liver cancer	0.00253	0.00272	CcSEcCtD
Nabilone—Syncope—Epirubicin—liver cancer	0.00252	0.00271	CcSEcCtD
Nabilone—Leukopenia—Epirubicin—liver cancer	0.00252	0.00271	CcSEcCtD
Nabilone—Back pain—Doxorubicin—liver cancer	0.00252	0.00271	CcSEcCtD
Nabilone—Palpitations—Epirubicin—liver cancer	0.00249	0.00268	CcSEcCtD
Nabilone—Loss of consciousness—Epirubicin—liver cancer	0.00247	0.00266	CcSEcCtD
Nabilone—Cough—Epirubicin—liver cancer	0.00246	0.00264	CcSEcCtD
Nabilone—Vision blurred—Doxorubicin—liver cancer	0.00245	0.00264	CcSEcCtD
Nabilone—Convulsion—Epirubicin—liver cancer	0.00244	0.00262	CcSEcCtD
Nabilone—Hypertension—Epirubicin—liver cancer	0.00243	0.00261	CcSEcCtD
Nabilone—Ill-defined disorder—Doxorubicin—liver cancer	0.00242	0.0026	CcSEcCtD
Nabilone—Anaemia—Doxorubicin—liver cancer	0.00241	0.00259	CcSEcCtD
Nabilone—Myalgia—Epirubicin—liver cancer	0.0024	0.00258	CcSEcCtD
Nabilone—Chest pain—Epirubicin—liver cancer	0.0024	0.00258	CcSEcCtD
Nabilone—Arthralgia—Epirubicin—liver cancer	0.0024	0.00258	CcSEcCtD
Nabilone—Agitation—Doxorubicin—liver cancer	0.00239	0.00257	CcSEcCtD
Nabilone—Anxiety—Epirubicin—liver cancer	0.00239	0.00257	CcSEcCtD
Nabilone—Discomfort—Epirubicin—liver cancer	0.00237	0.00255	CcSEcCtD
Nabilone—Malaise—Doxorubicin—liver cancer	0.00235	0.00253	CcSEcCtD
Nabilone—Dry mouth—Epirubicin—liver cancer	0.00234	0.00252	CcSEcCtD
Nabilone—Vertigo—Doxorubicin—liver cancer	0.00234	0.00252	CcSEcCtD
Nabilone—Syncope—Doxorubicin—liver cancer	0.00233	0.00251	CcSEcCtD
Nabilone—Leukopenia—Doxorubicin—liver cancer	0.00233	0.00251	CcSEcCtD
Nabilone—Confusional state—Epirubicin—liver cancer	0.00232	0.00249	CcSEcCtD
Nabilone—Palpitations—Doxorubicin—liver cancer	0.0023	0.00248	CcSEcCtD
Nabilone—Loss of consciousness—Doxorubicin—liver cancer	0.00229	0.00246	CcSEcCtD
Nabilone—Infection—Epirubicin—liver cancer	0.00228	0.00245	CcSEcCtD
Nabilone—Cough—Doxorubicin—liver cancer	0.00227	0.00244	CcSEcCtD
Nabilone—Shock—Epirubicin—liver cancer	0.00226	0.00243	CcSEcCtD
Nabilone—Convulsion—Doxorubicin—liver cancer	0.00226	0.00243	CcSEcCtD
Nabilone—Hypertension—Doxorubicin—liver cancer	0.00225	0.00242	CcSEcCtD
Nabilone—Tachycardia—Epirubicin—liver cancer	0.00224	0.00241	CcSEcCtD
Nabilone—Hyperhidrosis—Epirubicin—liver cancer	0.00222	0.00239	CcSEcCtD
Nabilone—Chest pain—Doxorubicin—liver cancer	0.00222	0.00238	CcSEcCtD
Nabilone—Myalgia—Doxorubicin—liver cancer	0.00222	0.00238	CcSEcCtD
Nabilone—Arthralgia—Doxorubicin—liver cancer	0.00222	0.00238	CcSEcCtD
Nabilone—Anxiety—Doxorubicin—liver cancer	0.00221	0.00238	CcSEcCtD
Nabilone—Discomfort—Doxorubicin—liver cancer	0.00219	0.00236	CcSEcCtD
Nabilone—Anorexia—Epirubicin—liver cancer	0.00219	0.00236	CcSEcCtD
Nabilone—Dry mouth—Doxorubicin—liver cancer	0.00217	0.00233	CcSEcCtD
Nabilone—Hypotension—Epirubicin—liver cancer	0.00215	0.00231	CcSEcCtD
Nabilone—Confusional state—Doxorubicin—liver cancer	0.00214	0.00231	CcSEcCtD
Nabilone—Infection—Doxorubicin—liver cancer	0.00211	0.00227	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00209	0.00225	CcSEcCtD
Nabilone—Shock—Doxorubicin—liver cancer	0.00209	0.00225	CcSEcCtD
Nabilone—Insomnia—Epirubicin—liver cancer	0.00208	0.00223	CcSEcCtD
Nabilone—Tachycardia—Doxorubicin—liver cancer	0.00207	0.00223	CcSEcCtD
Nabilone—Paraesthesia—Epirubicin—liver cancer	0.00206	0.00222	CcSEcCtD
Nabilone—Hyperhidrosis—Doxorubicin—liver cancer	0.00205	0.00221	CcSEcCtD
Nabilone—Dyspnoea—Epirubicin—liver cancer	0.00205	0.0022	CcSEcCtD
Nabilone—Somnolence—Epirubicin—liver cancer	0.00204	0.0022	CcSEcCtD
Nabilone—Anorexia—Doxorubicin—liver cancer	0.00203	0.00218	CcSEcCtD
Nabilone—Dyspepsia—Epirubicin—liver cancer	0.00202	0.00217	CcSEcCtD
Nabilone—Decreased appetite—Epirubicin—liver cancer	0.002	0.00215	CcSEcCtD
Nabilone—Hypotension—Doxorubicin—liver cancer	0.00199	0.00214	CcSEcCtD
Nabilone—Fatigue—Epirubicin—liver cancer	0.00198	0.00213	CcSEcCtD
Nabilone—Constipation—Epirubicin—liver cancer	0.00196	0.00211	CcSEcCtD
Nabilone—Pain—Epirubicin—liver cancer	0.00196	0.00211	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00194	0.00208	CcSEcCtD
Nabilone—Insomnia—Doxorubicin—liver cancer	0.00192	0.00207	CcSEcCtD
Nabilone—Paraesthesia—Doxorubicin—liver cancer	0.00191	0.00205	CcSEcCtD
Nabilone—Dyspnoea—Doxorubicin—liver cancer	0.00189	0.00204	CcSEcCtD
Nabilone—Feeling abnormal—Epirubicin—liver cancer	0.00189	0.00204	CcSEcCtD
Nabilone—Somnolence—Doxorubicin—liver cancer	0.00189	0.00203	CcSEcCtD
Nabilone—Gastrointestinal pain—Epirubicin—liver cancer	0.00188	0.00202	CcSEcCtD
Nabilone—Dyspepsia—Doxorubicin—liver cancer	0.00187	0.00201	CcSEcCtD
Nabilone—Decreased appetite—Doxorubicin—liver cancer	0.00185	0.00199	CcSEcCtD
Nabilone—Fatigue—Doxorubicin—liver cancer	0.00183	0.00197	CcSEcCtD
Nabilone—Constipation—Doxorubicin—liver cancer	0.00182	0.00195	CcSEcCtD
Nabilone—Pain—Doxorubicin—liver cancer	0.00182	0.00195	CcSEcCtD
Nabilone—Abdominal pain—Epirubicin—liver cancer	0.00182	0.00195	CcSEcCtD
Nabilone—Body temperature increased—Epirubicin—liver cancer	0.00182	0.00195	CcSEcCtD
Nabilone—Feeling abnormal—Doxorubicin—liver cancer	0.00175	0.00188	CcSEcCtD
Nabilone—Gastrointestinal pain—Doxorubicin—liver cancer	0.00174	0.00187	CcSEcCtD
Nabilone—Hypersensitivity—Epirubicin—liver cancer	0.00169	0.00182	CcSEcCtD
Nabilone—Abdominal pain—Doxorubicin—liver cancer	0.00168	0.00181	CcSEcCtD
Nabilone—Body temperature increased—Doxorubicin—liver cancer	0.00168	0.00181	CcSEcCtD
Nabilone—Asthenia—Epirubicin—liver cancer	0.00165	0.00177	CcSEcCtD
Nabilone—Pruritus—Epirubicin—liver cancer	0.00162	0.00175	CcSEcCtD
Nabilone—Diarrhoea—Epirubicin—liver cancer	0.00157	0.00169	CcSEcCtD
Nabilone—Hypersensitivity—Doxorubicin—liver cancer	0.00157	0.00168	CcSEcCtD
Nabilone—Asthenia—Doxorubicin—liver cancer	0.00152	0.00164	CcSEcCtD
Nabilone—Dizziness—Epirubicin—liver cancer	0.00152	0.00163	CcSEcCtD
Nabilone—Pruritus—Doxorubicin—liver cancer	0.0015	0.00162	CcSEcCtD
Nabilone—Vomiting—Epirubicin—liver cancer	0.00146	0.00157	CcSEcCtD
Nabilone—Diarrhoea—Doxorubicin—liver cancer	0.00145	0.00156	CcSEcCtD
Nabilone—Rash—Epirubicin—liver cancer	0.00145	0.00156	CcSEcCtD
Nabilone—Dermatitis—Epirubicin—liver cancer	0.00145	0.00156	CcSEcCtD
Nabilone—Headache—Epirubicin—liver cancer	0.00144	0.00155	CcSEcCtD
Nabilone—Dizziness—Doxorubicin—liver cancer	0.0014	0.00151	CcSEcCtD
Nabilone—Nausea—Epirubicin—liver cancer	0.00136	0.00147	CcSEcCtD
Nabilone—Vomiting—Doxorubicin—liver cancer	0.00135	0.00145	CcSEcCtD
Nabilone—Rash—Doxorubicin—liver cancer	0.00134	0.00144	CcSEcCtD
Nabilone—Dermatitis—Doxorubicin—liver cancer	0.00134	0.00144	CcSEcCtD
Nabilone—Headache—Doxorubicin—liver cancer	0.00133	0.00143	CcSEcCtD
Nabilone—Nausea—Doxorubicin—liver cancer	0.00126	0.00136	CcSEcCtD
Nabilone—CNR1—BDNF signaling pathway—SHC3—liver cancer	0.00104	0.054	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—ALPL—liver cancer	0.000663	0.0345	CbGpPWpGaD
Nabilone—CNR2—G alpha (i) signalling events—CCR4—liver cancer	0.000634	0.033	CbGpPWpGaD
Nabilone—CNR2—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.000588	0.0306	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—ADAM17—liver cancer	0.000582	0.0303	CbGpPWpGaD
Nabilone—CNR1—N-cadherin signaling events—CTNNB1—liver cancer	0.00058	0.0302	CbGpPWpGaD
Nabilone—CNR1—N-cadherin signaling events—MAPK8—liver cancer	0.000553	0.0288	CbGpPWpGaD
Nabilone—CNR2—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.000504	0.0263	CbGpPWpGaD
Nabilone—CNR1—G alpha (i) signalling events—CCR4—liver cancer	0.000497	0.0259	CbGpPWpGaD
Nabilone—CNR1—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.000462	0.024	CbGpPWpGaD
Nabilone—CNR1—N-cadherin signaling events—PIK3CA—liver cancer	0.000399	0.0208	CbGpPWpGaD
Nabilone—CNR1—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.000395	0.0206	CbGpPWpGaD
Nabilone—CNR2—GPCR ligand binding—CCR4—liver cancer	0.000384	0.02	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—MAPK14—liver cancer	0.000304	0.0158	CbGpPWpGaD
Nabilone—CNR1—GPCR ligand binding—CCR4—liver cancer	0.000301	0.0157	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CHN2—liver cancer	0.000292	0.0152	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—APC—liver cancer	0.000281	0.0147	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—IFT88—liver cancer	0.000267	0.0139	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CHN2—liver cancer	0.000229	0.0119	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—TRIO—liver cancer	0.000226	0.0118	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—RAF1—liver cancer	0.000221	0.0115	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—CCR4—liver cancer	0.000217	0.0113	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—MTOR—liver cancer	0.000216	0.0112	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—IFT88—liver cancer	0.00021	0.0109	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—TRIO—liver cancer	0.000205	0.0107	CbGpPWpGaD
Nabilone—CNR2—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.000201	0.0105	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—CASP3—liver cancer	0.000198	0.0103	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—CCR4—liver cancer	0.000197	0.0103	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—JUN—liver cancer	0.000193	0.01	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—CTNNB1—liver cancer	0.000191	0.00996	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—MAPK8—liver cancer	0.000182	0.0095	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—TRIO—liver cancer	0.000177	0.00925	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—CCR4—liver cancer	0.00017	0.00886	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—STAT3—liver cancer	0.000167	0.00868	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—SHC3—liver cancer	0.000164	0.00853	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—TRIO—liver cancer	0.000161	0.0084	CbGpPWpGaD
Nabilone—CNR1—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.000158	0.00823	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—CCR4—liver cancer	0.000155	0.00805	CbGpPWpGaD
Nabilone—CNR2—GPCR ligand binding—F2—liver cancer	0.000153	0.00799	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—SHC3—liver cancer	0.000129	0.0067	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—FST—liver cancer	0.000127	0.00663	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—PRKCE—liver cancer	0.000125	0.0065	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—HRAS—liver cancer	0.000122	0.00634	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TRIO—liver cancer	0.000121	0.00632	CbGpPWpGaD
Nabilone—CNR1—GPCR ligand binding—F2—liver cancer	0.00012	0.00627	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CCR4—liver cancer	0.000116	0.00606	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—PRKCE—liver cancer	0.000113	0.00591	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—CSF2—liver cancer	0.00011	0.00575	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—AKT1—liver cancer	0.000107	0.0056	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—CSF2—liver cancer	0.0001	0.00523	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—FST—liver cancer	9.98e-05	0.0052	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—PRKCE—liver cancer	9.8e-05	0.0051	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TRIO—liver cancer	9.52e-05	0.00496	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—ADAM17—liver cancer	9.2e-05	0.00479	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CCR4—liver cancer	9.13e-05	0.00476	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—PRKCE—liver cancer	8.9e-05	0.00464	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—F2—liver cancer	8.67e-05	0.00452	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—CSF2—liver cancer	8.67e-05	0.00452	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PSMA4—liver cancer	8.65e-05	0.0045	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PSMD10—liver cancer	8.65e-05	0.0045	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—PIK3CG—liver cancer	8.3e-05	0.00432	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—F2—liver cancer	7.87e-05	0.0041	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—CSF2—liver cancer	7.87e-05	0.0041	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—PIK3CG—liver cancer	7.53e-05	0.00392	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—PIK3CD—liver cancer	7.29e-05	0.0038	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—ADAM17—liver cancer	7.22e-05	0.00376	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—F2—liver cancer	6.8e-05	0.00354	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PSMD10—liver cancer	6.78e-05	0.00353	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PSMA4—liver cancer	6.78e-05	0.00353	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PRKCE—liver cancer	6.7e-05	0.00349	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—PIK3CD—liver cancer	6.62e-05	0.00345	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—PIK3CG—liver cancer	6.51e-05	0.00339	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—PIK3CB—liver cancer	6.36e-05	0.00331	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—IGF2—liver cancer	6.35e-05	0.00331	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—F2—liver cancer	6.18e-05	0.00322	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CSF2—liver cancer	5.93e-05	0.00309	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—RAF1—liver cancer	5.91e-05	0.00308	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—PIK3CG—liver cancer	5.91e-05	0.00308	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—H2AFX—liver cancer	5.84e-05	0.00304	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—IL2—liver cancer	5.84e-05	0.00304	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—PIK3CB—liver cancer	5.77e-05	0.00301	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—PIK3CD—liver cancer	5.72e-05	0.00298	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—IL2—liver cancer	5.3e-05	0.00276	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TERT—liver cancer	5.28e-05	0.00275	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PRKCE—liver cancer	5.26e-05	0.00274	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—PIK3CD—liver cancer	5.2e-05	0.00271	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—PIK3CB—liver cancer	4.99e-05	0.0026	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—IGF2—liver cancer	4.98e-05	0.00259	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—KDR—liver cancer	4.83e-05	0.00252	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—MAPK14—liver cancer	4.8e-05	0.0025	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—ESR1—liver cancer	4.71e-05	0.00245	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—F2—liver cancer	4.65e-05	0.00242	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CSF2—liver cancer	4.65e-05	0.00242	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—RAF1—liver cancer	4.64e-05	0.00242	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—H2AFX—liver cancer	4.58e-05	0.00239	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—IL2—liver cancer	4.58e-05	0.00239	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—PIK3CB—liver cancer	4.53e-05	0.00236	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—APC—liver cancer	4.45e-05	0.00232	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PIK3CG—liver cancer	4.45e-05	0.00232	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—BRAF—liver cancer	4.18e-05	0.00218	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—IL2—liver cancer	4.16e-05	0.00217	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TERT—liver cancer	4.14e-05	0.00216	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PIK3CD—liver cancer	3.91e-05	0.00204	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—PIK3CA—liver cancer	3.87e-05	0.00202	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—SERPINE1—liver cancer	3.87e-05	0.00202	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—KRAS—liver cancer	3.83e-05	0.002	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—KDR—liver cancer	3.79e-05	0.00197	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—MAPK14—liver cancer	3.77e-05	0.00196	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—ESR1—liver cancer	3.69e-05	0.00192	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—F2—liver cancer	3.65e-05	0.0019	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—PIK3CA—liver cancer	3.52e-05	0.00183	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—RAF1—liver cancer	3.49e-05	0.00182	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PIK3CG—liver cancer	3.49e-05	0.00182	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—APC—liver cancer	3.49e-05	0.00182	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PIK3CB—liver cancer	3.41e-05	0.00178	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—MTOR—liver cancer	3.41e-05	0.00178	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—BRAF—liver cancer	3.28e-05	0.00171	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—HRAS—liver cancer	3.26e-05	0.0017	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CDKN1B—liver cancer	3.2e-05	0.00167	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—AKT1—liver cancer	3.17e-05	0.00165	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CASP3—liver cancer	3.14e-05	0.00163	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—IL2—liver cancer	3.13e-05	0.00163	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—IL6—liver cancer	3.12e-05	0.00162	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PIK3CD—liver cancer	3.07e-05	0.0016	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CCND1—liver cancer	3.05e-05	0.00159	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—JUN—liver cancer	3.05e-05	0.00159	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—PIK3CA—liver cancer	3.04e-05	0.00158	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—SERPINE1—liver cancer	3.04e-05	0.00158	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CTNNB1—liver cancer	3.02e-05	0.00157	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—KRAS—liver cancer	3.01e-05	0.00157	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—MMP9—liver cancer	2.96e-05	0.00154	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CDKN1A—liver cancer	2.95e-05	0.00154	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—MAPK8—liver cancer	2.88e-05	0.0015	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—AKT1—liver cancer	2.87e-05	0.0015	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—PIK3CA—liver cancer	2.76e-05	0.00144	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—RAF1—liver cancer	2.74e-05	0.00143	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—MTOR—liver cancer	2.68e-05	0.00139	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PIK3CB—liver cancer	2.68e-05	0.00139	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—VEGFA—liver cancer	2.66e-05	0.00139	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—STAT3—liver cancer	2.64e-05	0.00137	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—HRAS—liver cancer	2.55e-05	0.00133	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CDKN1B—liver cancer	2.51e-05	0.00131	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—AKT1—liver cancer	2.48e-05	0.00129	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CASP3—liver cancer	2.46e-05	0.00128	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—IL2—liver cancer	2.46e-05	0.00128	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—MYC—liver cancer	2.45e-05	0.00128	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—IL6—liver cancer	2.44e-05	0.00127	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TGFB1—liver cancer	2.44e-05	0.00127	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CCND1—liver cancer	2.4e-05	0.00125	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—JUN—liver cancer	2.39e-05	0.00125	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CTNNB1—liver cancer	2.37e-05	0.00124	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—MMP9—liver cancer	2.33e-05	0.00121	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CDKN1A—liver cancer	2.32e-05	0.00121	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—KRAS—liver cancer	2.26e-05	0.00118	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—MAPK8—liver cancer	2.26e-05	0.00118	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—AKT1—liver cancer	2.26e-05	0.00118	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—VEGFA—liver cancer	2.09e-05	0.00109	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PIK3CA—liver cancer	2.08e-05	0.00108	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—STAT3—liver cancer	2.07e-05	0.00108	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TP53—liver cancer	2.01e-05	0.00105	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—HRAS—liver cancer	1.92e-05	0.001	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—MYC—liver cancer	1.92e-05	0.001	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TGFB1—liver cancer	1.92e-05	0.000998	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—IL6—liver cancer	1.84e-05	0.000959	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—KRAS—liver cancer	1.78e-05	0.000925	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—AKT1—liver cancer	1.7e-05	0.000885	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PIK3CA—liver cancer	1.63e-05	0.00085	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TP53—liver cancer	1.58e-05	0.000822	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—HRAS—liver cancer	1.51e-05	0.000786	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—IL6—liver cancer	1.44e-05	0.000752	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—AKT1—liver cancer	1.33e-05	0.000694	CbGpPWpGaD
